Dextroamphetamine for cocaine-dependence treatment: A double-blind randomized clinical trial

John Grabowski, Howard Rhoades, Joy Schmitz, Angela Stotts, Lee Ann Daruzska, Dan Creson, F. Gerard Moeller

Research output: Contribution to journalArticle

185 Citations (Scopus)

Abstract

A properly implemented agonist treatment regimen should improve retention and reduce illicit drug use. Cocaine-dependent subjects (N = 128) were enrolled in a 12-week randomized, double-blind, placebo-controlled trial. In the multistage dosing design, subjects initially received placebo (PBO) or 15 to 30 mg of dextroamphetamine sulfate, sustained-release capsules. At week 5, the dose doubled to 30 mg or 60 mg for active groups. Subjects attended the clinic twice a week, provided urine samples, obtained medication, and had one behavioral therapy session a week. Retention was best for the 15- to 30-mg group, whereas the proportion of benzoylecgonine-positive urine screens was, from lowest to highest, 30 to 60 mg, 15 to 30 mg, and PBO at study end. Dosing must be refined. The results provide support for additional examination of the agonist model in psychostimulant-dependence treatment.

Original languageEnglish (US)
Pages (from-to)522-526
Number of pages5
JournalJournal of Clinical Psychopharmacology
Volume21
Issue number5
DOIs
StatePublished - Oct 16 2001

Fingerprint

Cocaine-Related Disorders
Dextroamphetamine
Randomized Controlled Trials
Placebos
Urine
Street Drugs
Cocaine
Capsules
Therapeutics

Cite this

Dextroamphetamine for cocaine-dependence treatment : A double-blind randomized clinical trial. / Grabowski, John; Rhoades, Howard; Schmitz, Joy; Stotts, Angela; Daruzska, Lee Ann; Creson, Dan; Moeller, F. Gerard.

In: Journal of Clinical Psychopharmacology, Vol. 21, No. 5, 16.10.2001, p. 522-526.

Research output: Contribution to journalArticle

Grabowski, John ; Rhoades, Howard ; Schmitz, Joy ; Stotts, Angela ; Daruzska, Lee Ann ; Creson, Dan ; Moeller, F. Gerard. / Dextroamphetamine for cocaine-dependence treatment : A double-blind randomized clinical trial. In: Journal of Clinical Psychopharmacology. 2001 ; Vol. 21, No. 5. pp. 522-526.
@article{71c9f8d99a3c4fcc9f73e3634e60054c,
title = "Dextroamphetamine for cocaine-dependence treatment: A double-blind randomized clinical trial",
abstract = "A properly implemented agonist treatment regimen should improve retention and reduce illicit drug use. Cocaine-dependent subjects (N = 128) were enrolled in a 12-week randomized, double-blind, placebo-controlled trial. In the multistage dosing design, subjects initially received placebo (PBO) or 15 to 30 mg of dextroamphetamine sulfate, sustained-release capsules. At week 5, the dose doubled to 30 mg or 60 mg for active groups. Subjects attended the clinic twice a week, provided urine samples, obtained medication, and had one behavioral therapy session a week. Retention was best for the 15- to 30-mg group, whereas the proportion of benzoylecgonine-positive urine screens was, from lowest to highest, 30 to 60 mg, 15 to 30 mg, and PBO at study end. Dosing must be refined. The results provide support for additional examination of the agonist model in psychostimulant-dependence treatment.",
author = "John Grabowski and Howard Rhoades and Joy Schmitz and Angela Stotts and Daruzska, {Lee Ann} and Dan Creson and Moeller, {F. Gerard}",
year = "2001",
month = "10",
day = "16",
doi = "10.1097/00004714-200110000-00010",
language = "English (US)",
volume = "21",
pages = "522--526",
journal = "Journal of Clinical Psychopharmacology",
issn = "0271-0749",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Dextroamphetamine for cocaine-dependence treatment

T2 - A double-blind randomized clinical trial

AU - Grabowski, John

AU - Rhoades, Howard

AU - Schmitz, Joy

AU - Stotts, Angela

AU - Daruzska, Lee Ann

AU - Creson, Dan

AU - Moeller, F. Gerard

PY - 2001/10/16

Y1 - 2001/10/16

N2 - A properly implemented agonist treatment regimen should improve retention and reduce illicit drug use. Cocaine-dependent subjects (N = 128) were enrolled in a 12-week randomized, double-blind, placebo-controlled trial. In the multistage dosing design, subjects initially received placebo (PBO) or 15 to 30 mg of dextroamphetamine sulfate, sustained-release capsules. At week 5, the dose doubled to 30 mg or 60 mg for active groups. Subjects attended the clinic twice a week, provided urine samples, obtained medication, and had one behavioral therapy session a week. Retention was best for the 15- to 30-mg group, whereas the proportion of benzoylecgonine-positive urine screens was, from lowest to highest, 30 to 60 mg, 15 to 30 mg, and PBO at study end. Dosing must be refined. The results provide support for additional examination of the agonist model in psychostimulant-dependence treatment.

AB - A properly implemented agonist treatment regimen should improve retention and reduce illicit drug use. Cocaine-dependent subjects (N = 128) were enrolled in a 12-week randomized, double-blind, placebo-controlled trial. In the multistage dosing design, subjects initially received placebo (PBO) or 15 to 30 mg of dextroamphetamine sulfate, sustained-release capsules. At week 5, the dose doubled to 30 mg or 60 mg for active groups. Subjects attended the clinic twice a week, provided urine samples, obtained medication, and had one behavioral therapy session a week. Retention was best for the 15- to 30-mg group, whereas the proportion of benzoylecgonine-positive urine screens was, from lowest to highest, 30 to 60 mg, 15 to 30 mg, and PBO at study end. Dosing must be refined. The results provide support for additional examination of the agonist model in psychostimulant-dependence treatment.

UR - http://www.scopus.com/inward/record.url?scp=0034791235&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034791235&partnerID=8YFLogxK

U2 - 10.1097/00004714-200110000-00010

DO - 10.1097/00004714-200110000-00010

M3 - Article

C2 - 11593078

AN - SCOPUS:0034791235

VL - 21

SP - 522

EP - 526

JO - Journal of Clinical Psychopharmacology

JF - Journal of Clinical Psychopharmacology

SN - 0271-0749

IS - 5

ER -